ATE322544T1 - Hybrider faktor viii aus sequenzen von mensch und schwein - Google Patents

Hybrider faktor viii aus sequenzen von mensch und schwein

Info

Publication number
ATE322544T1
ATE322544T1 AT03075987T AT03075987T ATE322544T1 AT E322544 T1 ATE322544 T1 AT E322544T1 AT 03075987 T AT03075987 T AT 03075987T AT 03075987 T AT03075987 T AT 03075987T AT E322544 T1 ATE322544 T1 AT E322544T1
Authority
AT
Austria
Prior art keywords
factor viii
pig
sequences
human
hybrid factor
Prior art date
Application number
AT03075987T
Other languages
English (en)
Inventor
John S Lollar
Marschall S Runge
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25342308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE322544T1 publication Critical patent/ATE322544T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
AT03075987T 1992-04-07 1993-04-07 Hybrider faktor viii aus sequenzen von mensch und schwein ATE322544T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/864,004 US5364771A (en) 1992-04-07 1992-04-07 Hybrid human/porcine factor VIII

Publications (1)

Publication Number Publication Date
ATE322544T1 true ATE322544T1 (de) 2006-04-15

Family

ID=25342308

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93912141T ATE284963T1 (de) 1992-04-07 1993-04-07 Hybrider menschlich-schweinlicher faktor viii
AT03075987T ATE322544T1 (de) 1992-04-07 1993-04-07 Hybrider faktor viii aus sequenzen von mensch und schwein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93912141T ATE284963T1 (de) 1992-04-07 1993-04-07 Hybrider menschlich-schweinlicher faktor viii

Country Status (11)

Country Link
US (2) US5364771A (de)
EP (2) EP0638088B1 (de)
JP (2) JP3440097B2 (de)
AT (2) ATE284963T1 (de)
AU (1) AU682147B2 (de)
CA (1) CA2133203C (de)
DE (2) DE69334003T2 (de)
DK (2) DK1359222T3 (de)
ES (2) ES2261866T3 (de)
PT (1) PT1359222E (de)
WO (1) WO1993020093A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
JP2002526455A (ja) 1998-09-21 2002-08-20 ジェネティックス インスティテュート インク． 治療用たんぱく質に対する免疫応答を下方変調する方法
DK1129186T4 (da) * 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
EP1351986A2 (de) * 2001-01-12 2003-10-15 The American National Red Cross Verfahren und zusammensetzungen zur verminderung von heparansulfatproteoglykan-vermittelter entfernung von faktor viii
EP2110385A1 (de) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilisierte Faktor VIII mit manipulierten Disulfid-Bindungen
AU2002327430A1 (en) * 2001-08-08 2003-02-24 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
ATE417618T1 (de) 2001-10-05 2009-01-15 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
SI1750733T1 (sl) * 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (de) * 2006-12-22 2008-06-25 CSL Behring GmbH Veränderte Koagulationsfaktoren mit verlängerter in vivo Halbwertzeit
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
WO2011069164A2 (en) 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
BR112012017483A2 (pt) * 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
US9388452B2 (en) * 2010-04-08 2016-07-12 Baxalta Incorporated Methods for modeling protein stability
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
SMT201800586T1 (it) 2012-01-12 2019-01-11 Bioverativ Therapeutics Inc Riduzione dell'immunogenicita' contro il fattore viii negli individui che si sottopongono alla terapia con fattore viii
EP2804623B1 (de) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimäre faktor-vii polypeptide und verwendungen davon
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (de) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
LT3013855T (lt) 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP3082848B1 (de) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
AU5772886A (en) * 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins

Also Published As

Publication number Publication date
JP3495365B2 (ja) 2004-02-09
JP3440097B2 (ja) 2003-08-25
EP1359222A3 (de) 2003-11-19
DE69334003D1 (de) 2006-05-18
JP2003174876A (ja) 2003-06-24
EP1359222A2 (de) 2003-11-05
DK0638088T3 (da) 2005-04-25
PT1359222E (pt) 2006-07-31
CA2133203C (en) 2002-07-02
ES2261866T3 (es) 2006-11-16
CA2133203A1 (en) 1993-10-14
US5583209A (en) 1996-12-10
DE69333724D1 (de) 2005-01-20
AU4279993A (en) 1993-11-08
EP0638088A1 (de) 1995-02-15
EP0638088B1 (de) 2004-12-15
JPH07508404A (ja) 1995-09-21
DE69333724T2 (de) 2005-11-10
HK1058946A1 (en) 2004-06-11
AU682147B2 (en) 1997-09-25
EP1359222B1 (de) 2006-04-05
WO1993020093A1 (en) 1993-10-14
EP0638088A4 (de) 1996-06-26
US5364771A (en) 1994-11-15
ATE284963T1 (de) 2005-01-15
ES2235154T3 (es) 2005-07-01
DE69334003T2 (de) 2007-01-25
DK1359222T3 (da) 2006-06-19

Similar Documents

Publication Publication Date Title
DE69334003D1 (de) Hybrider Faktor VIII aus Sequenzen von Mensch und Schwein
DK0672138T3 (da) Kimære prokoagulante proteiner
DE69736068D1 (de) Faktor viii vom schwein und hybriden
DE69416492D1 (de) Härtungskontrolle von Silikongummizusammensetzungen
DE69328758D1 (de) Verfahren zur Herstellung von SOI-Bipolar- und MOS-Transistoren
DE69223027D1 (de) Verfahren und Klebstoff zur Herstellung von elektrischen und mechanischen Verbindungen
DE69304368D1 (de) IC-gesteuerter Gleichstrommotor
DE69408551D1 (de) Verfahren zur Herstellung von bemaltem Silikon-Elastomer
DE69312853D1 (de) Behandlung von Gummiartikeln
DE69320059D1 (de) Verfahren zur herstellung von 1,1,1,4,4,4-hexafluoro-2-buten und 1,1,1,4,4,4-hexafluorobutan
DE59302386D1 (de) Verwendung von polykondensaten und neue polykondensate
DE69327164D1 (de) Spannungserhöhungsschaltung zur Erzeugung von positiven und negativen erhöhten Spannungen
DE69311183D1 (de) Verfahren zur Herstellung von Acryloxy- oder Methacryloxygruppen enthaltenden Organosiliconen
DE59304719D1 (de) Verfahren zur Herstellung von Polysilazanen
DE69225702D1 (de) Verfahren zur Herstellung von kompakten Reinigungsmitteln
DE69206961D1 (de) Verfahren zur Dehydrierung von Kohlenwasserstoffen und von sauerstoffenthaltenden Kohlenwasserstoffen
DE69432507D1 (de) Verfahren und Geräte zur Erzeugung von Zeichnungsdaten
DE69317180D1 (de) Verfahren zur Herstellung von IC-Karten
ATE181549T1 (de) Verfahren zur herstellung von (s)-3-amino-1- substituiert-pirrolidine
DE69321848D1 (de) Verfahren zur herstellung von 1,1,1,2,3,3-hexafluorpropan und von tetrafluorchlorpropen
DE59106383D1 (de) Verfahren und einrichtung zur oxidation von wasserstoff.
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
DE69314445D1 (de) Verfahren zur Herstellung von Wasserstoffperoxyd
DE59101473D1 (de) Verfahren zur Herstellung von N-aryl-substituierten 2-Aminoalkyl-2-hydroxy-alkylaminen und N-arylsubstituierten Piperazinen.
DE59209120D1 (de) Mittel zur Härtung von hornartigen Körperteilen von Säugetieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties